

英語論文 総説

1. **Saji S**. The long and winding road for overcoming resistance to hormone therapy in breast cancer. (Editorial). *Breast Cancer*. July 2018;25(4):377-378, 2018.7 doi: 10.1007/s12282-018-0876-2
2. **Saji S, Kimura-Tsuchiya R, Sasaki E**. Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold? (Editorial). *Breast Cancer*. 23(1):1-3, 2016.
3. Sato F, **Saji S**, Toi M. Genomic tumor evolution of breast cancer. *Breast Cancer*. 23(1):4-11, 2016.
4. Ozaki A, Tanimoto T, **Saji S**. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer (Correspondence). *N Engl J Med*, 373:1672-1673, 2015.
5. Toi M, Masuda N, Ishiguro H, **Saji S**, Ohno S, Chow LW. Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. *Int J Biol Markers*. 30(2): e252-3, 2015.
6. **Saji S, Kimura-Tsuchiya R**. Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer. *Int J Clin Oncol*. 20(2):268-72, 2015.
7. Niikura N, **Saji S**, Tokuda Y, Iwata H. Brain Metastases in Breast Cancer. *Jpn J Clin Oncol*. 44(12): 1133-1140, 2014.

英語論文 原著

1. **Suga J**, Izumiyama K, Tanaka N, **Saji S**. Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7. *Biochemistry and Biophysics Reports*, in press, Dec 2018, 16:103-109 .doi: /10.1016/j.bbrep.2018.10.008
2. Gonda K, Tachiya Y, Hatakeyama Y, Momma T, Tamaoki T, Maejima Y, Rokkaku Y, **Saji S**, Shimomura K, Kono K. Poland syndrome accompanied by internal iliac artery supply disruption sequence: a case report. *Journal of Medical Case Reports*. Dec 2018, 12:312 DOI:10.1186/s13256-018-1823-8
3. Hosokawa K, Sugimori C, Ishiyama K, Takamatsu H, **Noji H**, Shichishima T, Obara N, Chiba S, Ninomiya H, Shirasugi Y, Nakamura Y, Ando K, Ueda Y, Yonemura Y, Kawaguchi T, Nishimura JI, Kanakura Y, Nakao S. Establishment of a flow cytometry assay for detecting paroxysmal nocturnal hemoglobinuria-type cells specific to patients with bone marrow failure. *Ann Hematol*. Dec 2018, 97(12): 2289–2297. doi: 10.1007/s00277-018-3443-1. PubMed PMID: 30039297.
4. Kiso M, Tanaka S, **Saji S**, Toi M, Sato F. Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. *Int J Cancer*. Dec 2018 1, 143 (11): 2905-2918 doi: 10.1002/ijc.31645.
5. Kameoka Y, Akagi T, Murai K, **Noji H**, Kato Y, Sasaki O, Ito S, Ishizawa K, Ishida Y, Ichinohasama R, Harigae H, Takahashi N. Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. *Int J Hematol*. Nov 2018;108(5):510-515. doi: 10.1007/s12185-018-2508-1. PubMed PMID: 30043334.
6. Yamamoto Y, Iwata H, Ueno T, Taira N, Kashiwaba M, Takahashi M, Tada H, Tsugawa K, Toyama T, Niikura N, Hara F, Fujisawa T, Yoshinami T, **Saji S**, Takano T, Masuda N, Morita S, Toi M, Ohno S. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. *Jpn J Clin Oncol*. Sep 2018;48(9):855-859 doi: 10.1093/jjco/hyy097.

7. Ueda Y, Obara N, Yonemura Y, **Noji H**, Masuko M, Seki Y, Wada K, Matsuda T, Akiyama H, Ikezoe T, Chiba S, Kanda Y, Kawaguchi T, Shichishima T, Nakakuma H, Okamoto S, Nishimura JI, Kanakura Y, Ninomiya H. Correction to: Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. *Int J Hematol.* Aug 2018; 108(2):233-235. doi: 10.1007/s12185-018-2486-3. PubMed PMID: 29980910.
8. Noguchi S, Nakaseko C, Nishiwaki K, Ogasawara H, Ohishi K, Tokuhira M, Noguchi M, Kimura H, Handa H, Mitani K, Miura M, Wakita H, Takahashi N; **STAT study group**. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan. *Int J Hematol.* Aug 2018; 108(2):176-183. doi: 10.1007/s12185-018-2459-6. PubMed PMID: 29713954.
9. **Saji S**. The long and winding road for overcoming resistance to hormone therapy in breast cancer. *Breast cancer (Tokyo, Japan)* 21 July 2018,5 (4) 377 - 378
10. Sato N, Masuda N, Morimoto T, Ueno T, Kanbayashi C, Kaneko K, Yasojima H, **Saji S**, Sasano H, Morita S, Ohno S, Toi M. Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. *Cancer Med.* July 2018. 7(7): 3044-3056 doi: 10.1002/cam4.1600
11. Miyake KK, Nakamoto Y, **Saji S**, Sugie T, Kurihara K, Kanao S, Ikeda DM, Toi M, Togashi K. Impact of physiological hormonal fluctuations on 18F-fluorodeoxyglucose uptake in breast cancer. *Breast Cancer Res Treat.* June 2018, 169(3): 437–446. doi: 10.1007/s10549-018-4711-4.
12. Ueda Y, Obara N, Yonemura Y, **Noji H**, Masuko M, Seki Y, Wada K, Matsuda T, Akiyama H, Ikezoe T, Chiba S, Kanda Y, Kawaguchi T, Shichishima T, Nakakuma H, Okamoto S, Nishimura JI, Kanakura Y, Ninomiya H. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. *Int J Hematol.* June 2018, 107(6): 656–665. doi: 10.1007/s12185-018-2409-3.
13. Fujita Y, Kishimoto M, Dohi O, Kamada K, Majima A, **Kimura-Tsuchiya R**, Yagi N, Konishi H, Naito Y, Harada Y, Tanaka H, Konishi E, Sugai T, Yanagisawa A. How to adjust endoscopic findings to histopathological findings of the stomach: a "histopathology-oriented" correspondence method helps to understand endoscopic findings. *Gastric Cancer.* 2018 May, 21(3): 573–577. DOI: 10.1007/s10120-017-0762-1
14. Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, **Saji S**, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A. Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. *Gastric Cancer.* 2018 May, 21(3):429–438. doi: 10.1007/s10120-017-0773-y.
15. Takuwa H, **Saji S**, Takada M, Takahara S, Yamauchi A. The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study. *Breast Dis.* Mar 2018 19. 37(7):1-6 doi: 10.3233/BD-170307
16. **Kimura-Tsuchiya R**, **Sasaki E**, Nakamura I, Suzuki S, Kawana S, Okouchi C, Fukushima T, Hashimoto Y, Suzuki S, **Saji S**. A Case of Squamous Cell Carcinoma of Unknown Primary that Responded to the Multi-Tyrosine Kinase Inhibitor Lenvatinib. *Case Rep Oncol.* 2018 Feb 9;11(1):75-80. doi: 10.1159/000486569.
17. Ueno T, **Saji S**, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Yamanaka T, Sasano H, Toi M. Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. *ESMO Open* .Feb 2018, 3 (2):1-8. e000314; DOI: 10.1136/esmoopen-2017-000314.

18. Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, **Saji S**, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced breast cancer: a subgroup analysis of the JBCRG-C06 Safari study. *Curr Med Res Opin.* Jan 2 2018 ; 34(1): 49–54. doi: 10.1080/03007995.2017.1400426.
19. Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, **Saji S**, Masuda N, Tokuda Y, Iwata H. Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis. *Breast Cancer Res Treat.* Jan 2018, 167(1): 81–87. doi: 10.1007/s10549-017-4489-9.
20. Ogiya R, Niikura N, Kumaki N, Yasojima H, Iwasa T, Kanbayashi C, Oshitanai R, Tsuneizumi M, Watanabe KI, Matsui A, Fujisawa T, **Saji S**, Masuda N, Tokuda Y, Iwata H. Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer. *Oncotarget.* 27;8(61):103671-103681, 2017. doi: 10.18632/oncotarget.22110.
21. Ishiguro H, **Saji S**, Nomura S, Tanaka S, Ueno T, Onoue M, Iwata H, Yamanaka T, Sasaki Y, Toi M. A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study). *Cancer Med.* 2017 Nov 13. doi: 10.1002/cam4.1258.
22. Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, **Saji S**, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with postmenopausal estrogen receptor-positive advanced breast cancer: a subgroup analysis of the JBCRG-C06 Safari study. *Curr Med Res Opin.* 2017 Nov 2:1-16. doi: 10.1080/03007995.2017.1400426.
23. Sawaki A, Yamada Y, Yamaguchi K, Nishina T, Doi T, Satoh T, Chin K, Boku N, Omuro Y, Komatsu Y, Hamamoto Y, Koizumi W, **Saji S**, Shah MA, Van Cutsem E, Kang YK, Iwasaki J, Kuriki H, Ohtsuka W, Ohtsu A. Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. *Gastric Cancer.* 2017 Oct 20. doi: 10.1007/s10120-017-0773-y.
24. **Kimura-Tsuchiya R**, Dohi O, Fujita Y, Yagi N, Majima A, Horii Y, Kitaichi T, Onozawa Y, Suzuki K, Tomie A, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Kishimoto M, Naito Y, Yanagisawa A, Itoh Y. Magnifying Endoscopy with Blue Laser Imaging Improves the Microstructure Visualization in Early Gastric Cancer: Comparison of Magnifying Endoscopy with Narrow-Band Imaging. *Gastroenterology research and practice.* 2017:8303046, 2017.
25. Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, **Saji S**, Masuda N, Tokuda Y, Iwata H. Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis. *Breast Cancer Res Treat.* 2017 Sep 11. doi: 10.1007/s10549-017-4489-9.
26. Fujita Y, Kishimoto M, Dohi O, Kamada K, Majima A, **Kimura-Tsuchiya R**, Yagi N, Konishi H, Naito Y, Harada Y, Tanaka H, Konishi E, Sugai T, Yanagisawa A. How to adjust endoscopic findings to histopathological findings of the stomach: a "histopathology-oriented" correspondence method helps to understand endoscopic findings. *Gastric Cancer.* 2017 Sep 5. [Epub ahead of print]
27. Ozaki A, Nomura S, Leppold C, Tsubokura M, Tanimoto T, Yokota T, **Saji S**, Sawano T, Tsukada M, Morita T, Ochi S, Kato S, Kami M, Nemoto T, Kanazawa Y, Ohira H. Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study. *BMC Cancer.* 2017. 17(1):423. doi: 10.1186/s12885-017-3412-4.

28. Kawamura F, Inaki M, Katafuchi A, Abe Y, Tsuyama N, Kurosu Y, Yanagi A, Higuchi M, Muto S, Yamaura T, Suzuki H, **Noji H**, Suzuki S, Yoshida MA, Sasatani M, Kamiya K, Onodera M, Sakai A. Establishment of induced pluripotent stem cells from normal B cells and inducing AID expression in their differentiation into hematopoietic progenitor cells. *Sci Rep*. 2017 May 10;7(1):1659. doi: 10.1038/s41598-017-01627-1.
29. Honma N, **Saji S**, Mikami T, Yoshimura N, Mori S, Saito Y, Murayama S, Harada N. Estrogen-Related Factors in the Frontal Lobe of Alzheimer's Disease Patients and Importance of Body Mass Index. *Sci Rep*. 2017. 7(1):726. doi:10.1038/s41598-017-00815-3.
30. Yokoyama H, Takahashi N, Katsuoka Y, Inomata M, Ito T, Meguro K, Kameoka Y, Tsumanuma R, Murai K, **Noji H**, Ishizawa K, Ito S, Onishi Y, Harigae H; Tohoku Hematology Forum. Evaluation of the safety and efficacy of recombinant soluble thrombomodulin for patients with disseminated intravascular coagulation associated with acute leukemia: multicenter prospective study by the Tohoku Hematology Forum. *Int J Hematol*. 2017 May;105(5):606-613.
31. Cao M, Shikama Y, Kimura H, **Noji H**, Ikeda K, Ono T, Ogawa K, Takeishi Y, Kimura J. Mechanisms of Impaired Neutrophil Migration by MicroRNAs in Myelodysplastic Syndromes. *J Immunol*. 2017 Mar 1;198(5):1887-1899.
32. Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, **Saji S**, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno S, Toi M. Outcomes of fulvestrant therapy among Japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari). *Breast Cancer Res Treat*. 163(3):545-554, 2017. doi: 10.1007/s10549-017-4212-x.
33. Dohi O, Yagi N, Majima A, Horii Y, Kitaichi T, Onozawa Y, Suzuki K, Tomie A, **Kimura-Tsuchiya R**, Tsuji T, Yamada N, Bito N, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Naito Y, Yanagisawa A, Itoh Y. Diagnostic ability of magnifying endoscopy with blue laser imaging for early gastric cancer: a prospective study. *Gastric cancer*. 20(2):297-303, 2017.
34. Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, **Noji H**, Sasaki O, Wano M, Itoh J, Kato Y, Shichishima T, Harigae H, Ishida Y; Tohoku Hematology Forum. Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan. *Leuk Lymphoma*. 2017 Jun;58(6):1509-1511.
35. Ueno T, **Saji S**, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M. Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. *BMC Cancer*. 16(1):230, 2016.
36. Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, **Saji S**, Toi M. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. *Breast Cancer Research*. 18(1):129, 2016.
37. Dohi O, Yagi N, Onozawa Y, **Kimura-Tsuchiya R**, Majima A, Kitaichi T, Horii Y, Suzuki K, Tomie A, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Naito Y, Itoh Y. Linked color imaging improves endoscopic diagnosis of active *Helicobacter pylori* infection. *Endoscopy International Open*. 4(7): E800-E805, 2016.
38. Fujita Y, Kishimoto M, Nakao R, **Kimura-Tsuchiya R**, Yagi N, Yanagisawa A. Incidence of lymphatic involvement in differentiated-type intramucosal gastric cancers as examined by endoscopic resection. *Gastric Cancer*. 19(1):192-197, 2016.
39. Tomie A, Dohi O, Yagi N, Kitae H, Majima A, Horii Y, Kitaichi T, Onozawa Y, Suzuki K, **Kimura-Tsuchiya R**, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Naito Y, Itoh Y. Blue Laser Imaging-Bright Improves Endoscopic Recognition of Superficial Esophageal Squamous Cell Carcinoma. *Gastroenterology Research and Practice*. 2016:6140854, 2016.

40. Takahashi N, Kameoka J, Takahashi N, Tamai Y, Murai K, Honma R, **Noji H**, Yokoyama H, Tomiya Y, Kato Y, Ishizawa K, Ito S, Ishida Y, Sawada K, Harigae H. Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. *International Journal of Hematology*. 10(3):344-357, 2016.
41. Ikeda K, Harada-Shirado K, Matsumoto H, **Noji H**, Ogawa K, Takeishi Y. Molecular response of e19a2 BCR-ABL1 chronic myeloid leukemia with double Philadelphia chromosome by dasatinib. *Journal of Clinical Oncology*. 34(14): e130-e133, 2016.
42. Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, **Noji H**, Sasaki O, Wano M, Itoh J, Kato Y, Shichishima T, Ishida Y, Harigae H, Sawada K; The Tohoku Hematology Forum. High prevalence of diffuse large B-cell lymphoma in occult hepatitis B virus-infected patients in the Tohoku district in Eastern Japan. *Journal of Medical Virology*. 88(12):2206-2210, 2016.
43. Ohkawara H, Shichishima-Nakamura A, Ikeda K, Sukegawa M, Furukawa M, Sano T, Ueda K, Kimura S, Yoshihisa A, **Noji H**, Ogawa K, Takeishi Y. Infected pancreatic pseudocyst ruptured into stomach and colon associated with splenic artery pseudoaneurysm. *Journal of the Pancreas*. 17(3):324-327, 2016.
44. Abe Y, Miura T, Yoshida MA, Ujiie R, Kurosu Y, Kato N, Katafuchi A, Tsuyama N, Kawamura F, Ohba T, Inamasu T, Shishido F, **Noji H**, Ogawa K, Yokouchi H, Kanazawa K, Ishida T, Muto S, Ohsugi J, Suzuki H, Ishikawa T, Kamiya K, Sakai A. Analysis of chromosome translocation frequency after a single CT scan in adults. *Journal of Radiation Research*. 57(3):220-226, 2016.
45. Ozaki A, Leppold C, Tsubokura M, Tanimoto T, **Saji S**, Kato S, Kami M, Tsukada M, Ohira H. Social isolation and cancer management after the 2011 triple disaster in Fukushima, Japan: A case report of breast cancer with patient and provider delay. *Medicine (Baltimore)*. 95(26): e4027, 2016.
46. Shikama Y, Cao M, Ono T, Feng X, **Noji H**, Kimura H, Ogawa K, Suzuki Y, Ikeda K, Takeishi Y, Kimura J. Reduction of c-Fos via overexpression of miR-34a results in enhancement of TNF- α production by LPS in neutrophils from myelodysplastic syndrome patients. *PLOS ONE*. 11(18): e0158527, 2016.
47. Yagata H, Ohtsu H, Komoike Y, **Saji S**, Takei H, Nakamura T, Ohashi Y, Iwase T, Shimozuma K. Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole. *Supportive Care in Cancer*. 24(2):683-689, 2016.
48. Matsuyama T, Ishikawa T, Okayama T, Oka K, Adachi S, Mizushima K, **Kimura R**, Okajima M, Sakai H, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Kokura S, Naito Y, Itoh Y. Tumor inoculation site affects the development of cancer cachexia and muscle wasting. *Int J Cancer*. 137(11):2558-65, 2015.
49. Honma N, Horii R, Ito Y, **Saji S**, Younes M, Iwase T, Akiyama F. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. *BMC Cancer*. 15(1):698, 2015.
50. Hojo T, Masuda N, Mizutani T, Shibata T, Kinoshita T, Tamura K, Hara F, Fujisawa T, Inoue K, **Saji S**, Nakamura K, Fukuda H, Iwata H. Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204. *Jpn J Clin Oncol*. 45(10):983-6 2015.
51. Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Yamauchi H, **Saji S**, Iwata H. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. *Breast Cancer Res Treat*. 49(1):277-84. 2015.

52. Kurebayashi J, Miyoshi Y, Ishikawa T, **Saji S**, Sugie T, Suzuki T, Takahashi S, Nozaki M, Yamashita H, Tokuda Y, Nakamura S. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. *Breast Cancer*. 22(3):235-44. 2015.
53. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; **CLEOPATRA Study Group**. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med*. 372(8):724-34, 2015.
54. Honma N, Horii R, Iwase T, **Saji S**, Younes M, Ito Y, Akiyama F, Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy, *Breast Cancer*, 22(1):71-8, 2015.
55. Takemoto K, Hatano E, Iwaisako K, Takeiri M, Noma N, Ohmae S, Toriguchi K, Tanabe K, Tanaka H, Seo S, Taura K, Machida K, Takeda N, **Saji S**, Uemoto S, Asagiri M. Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure. *FEBS Open Bio*. Sep 6; 4: 777-87. 2014.
56. Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe KI, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Tokuda Y, **Saji S**, Iwata H. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. *Breast Cancer Res Treat*. 147(1):103-12, 2014.
57. Honma N, Horii R, Iwase T, **Saji S**, Younes M, Ito Y, Akiyama F. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy. *Breast*. 23(6):754-62, 2014.
58. Ueno T, Masuda N, Yamanaka T, **Saji S**, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M. Evaluating the 21-gene assay Recurrence Score as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer, *Int J Clin Oncol*. 9(4):607-13, 2014.
59. **Kimura-Tsuchiya R**, Ishikawa T, Kokura S, Mizushima K, Adachi S, Okajima M, Matsuyama T, Okayama T, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Yagi N, Naito Y, Itoh Y. The inhibitory effect of heat treatment against epithelial-mesenchymal transition (EMT) in human pancreatic adenocarcinoma cell lines. *J Clin Biochem Nutr*. 55(1):56-61, 2014.

日本語論文 総説

1. **佐治重衡**
チームで支える乳がんの内分泌療法
日本医師会雑誌, 147(3), :495-499, 2018. 6
2. 村上祐子、立花和之進、大竹徹、**佐治重衡**
内分泌療法と分子標的薬の併用
日本臨床, 76(5) : 760-767, 2018. 5
3. **木村礼子、佐々木栄作、野地秀義、佐治重衡**
がん転移学(下) V. 再発転移抑制のための周術期治療 4. 乳癌
日本臨床 75(suppl 9) :27-31, 2017.
4. **佐治重衡**
特集 がん診療 内科医が知りたい30のエッセンス
再発・転移乳がんの診断・治療について教えてください

Medicina, 54(8):1246-1249, 2017.

5. 阿部宣子、佐治重衡、阿部貞彦、野田勝、岡野舞子、立花和之進、吉田清香、大竹徹
乳腺疾患と黄体ホルモン
産婦人科の実際, 66(5):619-624, 2017.
6. 佐治重衡、木村礼子、佐々木栄作、野地秀義
内分泌療法と分子標的治療薬との併用
日本臨牀 増刊号、75 (suppl 3): 326-331, 2017.
7. 鹿目将至、佐治重衡
ホルモン抵抗性乳がんに対する内分泌療法と分子標的薬との併用
腫瘍内科、18(3):214-219, 2016.
8. 阿部宣子、大竹徹、佐治重衡
特集：乳癌発症リスクとその対策 女性ホルモンと乳癌
乳癌の臨床、31(3): 187-192, 2016.
9. 佐治重衡
One point lesson スライドの作り方
Cancer Board of the Braest, 2(1), 69-71, 2016.
10. 鈴木礼子、佐治重衡
やせ・肥満と乳がん発生リスク—女性のライフステージ別に異なる可能性について—
癌と化学療法、42(5):525-528, 2015.
11. 大津敦、赤司浩一、佐治重衡、吉村清
座談会 抗体治療の新展開
がん分子標的治療、13(2):224-231, 2015.
12. 佐治重衡
総説論文というもの (エッセイ)
日本癌病態治療研究会誌、21(1):47-48, 2015.
13. 山口絢音、佐治重衡、戸井雅和
閉経前ホルモン受容体陽性早期乳がんに対する術後内分泌療法
腫瘍内科、15(5):438-443, 2015.
14. 津田萌、石黒洋、佐治重衡
内分泌療法薬の作用機序と副作用：概論
日本臨牀 73(suppl 2), 291-297, 2015.
15. 今村知世、佐治重衡
ホルモン受容体陽性乳がんに対するタモキシフェン治療と CYP2D6 遺伝子多型
がん分子標的治療、12(4): 449-455, 2014.
16. 佐藤史顕、佐治重衡、戸井雅和
State of the Art: Genetic tumor evolution
Cancer Board 乳癌, 7(2), 23-30, 2014.
17. 林直輝、山内英子、佐治重衡
乳癌患者におけるアロマターゼ阻害薬と骨粗鬆症
The BONE, 28(4), 69-74, 2014.

18. **佐治重衡、木村礼子**
閉経前、腋窩リンパ節転移陽性、Luminal A 乳癌の治療 b) 術前薬物療法
外科、76(13): 1550-1553, 2014.
19. 清水華子、諏訪裕文、**佐治重衡**
抗 HER2 療法の新時代 ALTT0 試験の結果から
腫瘍内科, 14(3):268-272, 2014.
20. 河口浩介、鈴木栄治、**佐治重衡**
乳がんの抗 HER2 療法耐性機序とその克服
がん分子標的治療 Vol. 12No. 2: 13-19, 2014
21. 土肥 統、八木信明、**木村礼子**、鎌田和浩、内藤裕二、伊藤義人
残胃の早期胃癌に対する ESD の実際
消化器の臨床, 17(3):264-268, 2014.

書籍

1. 編集委員：**佐治重衡**
新臨床腫瘍学ーがん薬物療法専門医のためにー(改訂第5版)，日本臨床腫瘍学会編，南江堂，20180730
2. **木村礼子、佐治重衡**
第2章 乳癌 術後・転移・再発：Tamoxifenm, Exemestane、tamoxifen + LHRH agonist 療法、exemestane + LHRH agonist 療法
エビデンスに基づいた癌化学療法ハンドブック 2018、大津敦 総監修、p. 246-247, 256-257, 264-266, 267-268. メディカルレビュー社，2018.
3. **佐治重衡**（診療ガイドライン委員会 副委員長、患者向けガイドライン小委員会 委員長）
乳癌診療ガイドライン ①治療編、②疫学・診断編 2018年版
4. 日本乳癌学会 編、金原出版、20180516
5. **佐治重衡**
進行再発乳がんに対する薬物療法
乳がん薬物療法副作用マネジメント 2017.
6. 河口浩介、**佐治重衡**
乳がんの治療 内分泌療法
乳がん患者ケアパーフェクトブック、阿部恭子、矢形寛 編、学研メディカル秀潤社、116-129, 2017.
7. 乳腺作成者；津川浩一郎、**佐治重衡**、清水千佳子、土屋恭子、坂東裕子、桑原章、古井辰郎
小児、思春期、若年がん患者の妊孕性温存に関する診療ガイドライン 2017年版
一般社団法人 日本癌治療学会編、金原出版、2017
8. 青木大輔・上野直人・中村清吾監修、**佐治重衡**・清水千佳子編
チームで学ぶ女性がん患者のための ホルモンマネジメント
篠原出版、2017.

9. **佐治重衡**
分子標的薬の進歩 2016~2017
これからの乳癌診療 2017-2018、園尾博司監修、福田護・池田正・佐伯俊昭・鹿間直人編 金原出版、38-43、2017.
10. **木村礼子、佐治重衡**
乳癌 術後・転移・再発 : Exemestane、tamoxifen + LHRH agonist 療法、exemestane + LHRH agonist 療法
エビデンスに基づいた癌化学療法ハンドブック 2017、大津敦 総監修、p. 246-247, 254-258, メディカルレビュー社, 2017.
11. **佐治重衡** (監修)
ホルモン療法薬 (p420-421)、乳房のがん (p476-487)
薬がみえる vol.3 第1版、メディックメディア, 2016.
12. **木村礼子、佐治重衡**
第II章乳癌薬物療法の実際 分子標的治療—4 臨床試験と実際の投与方法 ベバシズマブ
オンコロジークリニカルガイド 乳癌薬物療法 (第2版), 木下貴之, 戸井雅和編, pp296-303, 南山堂, 2016.
13. **野地秀義、七島 勉**
第5章 血液科疾患の診療 A 赤血球系疾患 4. 発作性夜間ヘモグロビン尿症.
血液科研修ノート, 神田善伸 責任編集, p. 238-242, 診断と治療社, 2016.
14. **佐々木栄作、佐治重衡**
G-2-1 ホルモン受容体陽性乳癌に対する治療戦略
乳癌診療のための分子病理エッセンシャル, 津田均、木下貴之、田村研治編、南山堂、p195-205、2016.
15. **佐治重衡**
2-2 B. 原発乳癌 術後内分泌療法
乳腺腫瘍学 第2版、日本乳癌学会編、金原出版株式会社、228-236、2016.
16. **佐々木栄作**
CQ23 DS療法(DTX+S-1)をどう使いこなすか?
CQ24 weekly PTX療法をどう使いこなすか?
胃がん薬物療法Q&A、佐藤温編、ヴァンメディカル、72-75、2015.
17. **佐々木栄作**
第1章抗がん剤の副作用と治療 8. 神経障害 116-121
第4章レジメン別の副作用 2. 頭頸部がん 346-348
改訂版 がん化学療法副作用対策ハンドブック、岡元るみ子・佐々木常雄編、羊土社、2015.
18. 山口絢音、**佐治重衡**
IV. A. 2 術後ホルモン療法は何年間で適切か?
EBM がん化学療法・分子標的治療法 2016-2017edition、西條長宏監修、朴成和、大江裕一郎、南博信、直江和樹編、中外医学社、338-343、2015.
19. 澤木正孝、**佐治重衡**
22. 乳癌
新臨床腫瘍学-がん薬物療法専門医のために-(改訂第4版)、日本臨床腫瘍学会編、南江堂、362-373、2015.

20. **佐治重衡**

乳癌の分子生物学と mTOR

エベロリムスによる乳癌治療の新展開、野口眞三郎編、メデイカルレビュー社、30-37、2014.